Large study links oral menopause hormone therapy to blood clot risk at any dose
First published Tue, Sep 29
A large study has confirmed a risk of thrombosis associated with oral hormone replacement therapy for menopause. The risk persists regardless of the dose of the treatment, and the danger concerns the tablets rather than other routes of administration.123
Coverage of the findings focuses on the route of administration: the blood clot risk is reported only with the pills, while other delivery methods are not implicated in the same way. One outlet frames the administration route as multiplying cardiovascular risks.34
A further report warns of cardiac risks from oral tablets, citing the same large study. The study is described as vast, and the alert concerns the oral form of the treatment.5
